Oncocyte Announces Initiatives to Focus Corporate Strategy
16 déc. 2022 08h00 HE
|
Oncocyte Corporation
IRVINE, Calif., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced a reduction in force involving over 40% of Oncocyte’s workforce...
Oncocyte Announces the Appointment of Louis E. Silverman as a Member of Its Board of Directors
30 nov. 2022 18h05 HE
|
Oncocyte Corporation
IRVINE, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights...
Oncocyte Announces Executive Leadership Changes
30 nov. 2022 18h00 HE
|
Oncocyte Corporation
IRVINE, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights...
Oncocyte Reports Third Quarter 2022 Financial Results
10 nov. 2022 16h30 HE
|
Oncocyte Corporation
IRVINE, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights...
Oncocyte to Announce Third Quarter 2022 Financial Results
27 oct. 2022 16h01 HE
|
Oncocyte Corporation
IRVINE, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights...
DetermaIO™ Clinical Test to be used in SWOG Cancer Research Network Biomarker Study for Breast Cancer
06 oct. 2022 08h00 HE
|
Oncocyte Corporation
IRVINE, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights...
Oncocyte Announces Unanimous Recommendation from the Advisory Panel for Clinical Diagnostic Laboratory Tests on DetermaRx to CMS
07 sept. 2022 08h00 HE
|
Oncocyte Corporation
IRVINE, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights...
Oncocyte to Participate at the Lake Street 6th Annual Best Ideas Growth Conference
31 août 2022 16h01 HE
|
Oncocyte Corporation
IRVINE, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights...
Oncocyte Announces Five-Year VA Contract for DetermaRx
30 août 2022 16h27 HE
|
Oncocyte Corporation
IRVINE, Calif., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized...
Oncocyte Announces Publication of the Validation of DetermaIO in Predicting Immune Therapy Response in Metastatic Bladder Cancer
24 août 2022 08h00 HE
|
Oncocyte Corporation
IRVINE, Calif., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights...